# Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
Canonical URL: https://biopharmsignal.com/news/KRYS/krystal-biotech-to-announce-interim-clinical-update-from-highest-dose-cohort-of--a44be477
Ticker: KRYS
Company: Krystal Biotech
Source: Krystal Biotech
Published: 2026-01-07 21:05 EST
## Summary

Investor call to be held January 8 at 4:30 pm ET to discuss data update and next steps...

## Article Body
Investor call to be held January 8 at 4:30 pm ET to discuss data update and next steps

January 07, 2026 16:05 ET | Source: Krystal Biotech, Inc.

PITTSBURGH, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that it will host an investor conference call and webcast tomorrow, Thursday, January 8, 2026, at 4:30 pm ET, to disclose an interim clinical update from CORAL-1, the Company’s multi-center, dose escalation Phase 1 study evaluating KB407 in patients with cystic fibrosis. The interim clinical update will focus on results from patients in the highest dose cohort of CORAL-1 and include molecular assessments of KB407 transduction and wild-type cystic fibrosis transmembrane conductance regulator (CFTR) protein expression following inhaled administration of KB407.

Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53466 . For those unable to listen to the live webcast, an archived version will also be available on the Investors section of the Company’s website for at least 30 days.

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK ® , the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com , and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

CONTACT Investors and Media: Stéphane Paquette Krystal Biotech spaquette@krystalbio.com
## Recent Company News
- 2026-07-23 21:00 EST — [Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026](https://biopharmsignal.com/news/KRYS/krystal-biotech-to-report-second-quarter-2026-financial-results-on-august-3-2026-2f96b902) — Source: Krystal Biotech
- 2026-05-18 12:00 EST — [Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa](https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-united-kingdom-mhra-approval-of-vyjuvek-for-the-treatm-23d2eafe) — Source: Krystal Biotech
- 2026-05-07 12:00 EST — [Krystal Biotech to Present at BofA Securities 2026 Health Care Conference](https://biopharmsignal.com/news/KRYS/krystal-biotech-to-present-at-bofa-securities-2026-health-care-conference-f4e6ec6b) — Source: Krystal Biotech
- 2026-05-04 11:00 EST — [Krystal Biotech Announces First Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-first-quarter-2026-financial-and-operating-results-9aa0ae94) — Source: Krystal Biotech
- 2026-04-30 12:00 EST — [Krystal Biotech to Present at Upcoming Scientific Conferences](https://biopharmsignal.com/news/KRYS/krystal-biotech-to-present-at-upcoming-scientific-conferences-5a0d2417) — Source: Krystal Biotech
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)